A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: Clinical outcome and effect on subsequent immune recovery

Biology of Blood and Marrow Transplantation

Volumn 2, Issue 1, 1996, Pages 44-53

  Sullivan, Keith M ^a,b   Storek, Jan ^a   Kopecky, Kenneth J ^a   Jocom, Jane ^a   Longton, Gary ^a   Flowers, Mary ^a   Siadak, Muriel ^a   Nims, Janet ^a   Witherspoon, Robert P ^a   Anasetti, Claudio ^a   Appelbaum, Frederick R ^a   Bowden, Raleigh A ^a   Buckner, C Dean ^a   Crawford, Stephen W ^a   Deeg, H Joachim ^a   Hansen, John A ^a   McDonald, George B ^a   Sanders, Jean E ^a   Storb, Rainer ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Bone marrow transplantation; Chronic graft vs. host disease; Infection; Intravenous immunoglobulin

Indexed keywords

IMMUNOGLOBULIN;

ADOLESCENT; ADULT; ARTICLE; BLOOD DISEASE; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; CLINICAL TRIAL; COMMUNICABLE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; COMMUNICABLE DISEASES; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; RECURRENCE; TREATMENT OUTCOME;

EID: 0030072985     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Atkinson K, Storb R, Prentice RL, Weiden PL, Witherspoon RP, Sullivan K, Noel D, Thomas ED: Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 53:720, 1979.
2. Sullivan KM, Agura E, Anasetti C, Appelbaum FR, Badger C, Bearman S, Erickson K, Flowers M, Hansen JA, Loughran T, Martin P, Matthews D, Petersdorf E, Radich J, Riddell S, Rovira D, Sanders J, Schuening F, Siadak M, Storb R, Witherspoon RP: Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250, 1991.
3. Witherspoon RP, Storb R, Ochs HD, Flournoy N, Kopecky KJ, Sullivan KM, Deeg HJ, Sosa R, Noel DR, Atkinson K, Thomas ED: Recovery of antibody production in human allogeneic marrow graft recipients: Influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 58:360, 1981.
4. Atkinson K, Farewell V, Storb R, Tsoi M-S, Sullivan KM, Witherspoon RP, Fefer A, Clift R, Goodell B, Thomas ED: Analysis of late infections after human bone marrow transplantation: Role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 60:714, 1982.
5. Lum LG: A review: The kinetics of immune reconstitution after human marrow transplantation. Blood 69:369, 1987.
6. Aucouturier P, Barra A, Intrator L, Cordonnier C, Schulz D, Duarte F, Vernant J-P, Preud'homme J-L: Long lasting IgG subclass and antibacterial polysaccharide antibody deficiency after allogeneic bone marrow transplantation. Blood 70:779, 1987.
7. Holland HK, Wingard JR, Beschorner WE, Saral R, Santos GW: Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG. Blood 72:621, 1988.
8. Sheridan JF, Tutschka PJ, Sedmak DD, Copelan EA: Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 75:1583, 1990.
9. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB, Schubert MM, Atkinson K, Thomas ED: Chronic graft-versus-host disease in 52 patients: Adverse natural course and successful treatment with combination immunosuppression. Blood 57:267, 1981.
10. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, Deeg HJ, Sanders JE, Doney KC, Appelbaum FR, McGuffin R, McDonald GB, Meyers J, Schubert MM, Gauvreau J, Shulman HM, Sale GE, Anasetti C, Loughran TP, Strom S, Nims J, Thomas ED: Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-versus-host disease: Prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72:546, 1988.
11. Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS, Beschorner WE, Cahill RA, Miller DF, Harrison D: Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74:1428, 1989.
12. Buckley RH, Schiff RI: The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 326:110, 1991.
13. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228, 1981.
14. Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med 326:107, 1991.
15. Newburger JW, Takahasbi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, Glode MP, Mason WH, Reddy V, Sanders SP, Shulman ST, Wiggins JW, Hicks RV, Fulton DR, Lewis AB, Leung DYM, Colton T, Rosen FS, Melish ME: The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 315:341, 1986.
16. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 329:1993, 1993.
17. Meyers JD, Leszczynski J, Zaia JA, Flournoy N, Newton B, Snydman DR, Wright GG, Levin MJ, Thomas ED: Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 98:442, 1983.
18. Condie RM, O'Reilly RJ: Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Am J Med 76 (suppl. 3A):134, 1984.
19. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, Meyers JD: Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 314:1006, 1986.
20. Ringden O, Pihlstedt P, Volin L, Nikoskelainen J, Lonnqvist B, Ruutu P, Ruutu T, Toivanen A, Wahren B: Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 2:299, 1987.
21. Winston DJ, Ho WG, Lin C-H, Bartoni K, Budinger MD, Gale RP, Champlin RE: Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106:12, 1987.
22. Petersen FB, Bowden RA, Thornquist M, Meyers JD, Buckner CD, Counts GW, Nelson MT, Newton BA, Sullivan KM, McIver J, Thomas ED: The effect of prophylactic intravenous immune globulin on the incidence of septicemia in marrow transplant recipients. Bone Marrow Transplant 2:141, 1987.
23. Graham-Pole J, Camitta B, Casper J, Elfenbein G, Gross S, Herzig R, Koch P, Mahoney D, Marcus R, Munoz L, Pick T, Spruce W, Steuber P, Weiner R: Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: A pediatric oncology group study. Bone Marrow Transplant 3:559, 1988.
24. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, Counts GW, Bowden RA, Petersen FB, Witherspoon RP, Budinger MD, Schwartz RS, Appelbaum FR, Clift RA, Hansen JA, Sanders JE, Thomas ED, Storb R: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705, 1990.
25. Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, Collins RH, Stevens DA, Herzig GP: High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 118:937, 1993.
26. Bass EB, Powe NR, Goodman SN, Graziano SL, Griffiths RI, Kickler TS, Wingard JR: Efficacy of immune globulin in preventing complications of bone marrow transplantation: A meta-analysis. Bone Marrow Transplant 12:273, 1993.
27. Dixon FJ, Jacot-Guillarmod H, McConaby PJ: The effect of passively administered antibody on antibody synthesis. J Exp Med 125:1119, 1967.
28. Kondo N, Ozawa T, Mushiake K, Motoyoshi F, Kameyama T, Kasahara K, Kaneko H, Yamashina M, Kato Y, Orii T: Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J Clin Immunol 11:152, 1991.
29. Bowden RA, Slichter SJ, Sayers MH, Mori M, Cays MJ, Meyers JD: Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 78:246, 1991.
30. Bowden RA, Fisher LD, Rogers K, Cays M, Meyers JD: Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 164:483, 1991.
31. Schwartz RS: Overview of the biochemistry and safety of a new native intravenous gamma globulin, IGIV, pH 4.25. Am J Med 83 (suppl. 4A):46, 1987.
32. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314:729, 1986.
33. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, Loughran TP, Hill R, Shields A, Yee G, Shulman H, Nims J, Strom S, Thomas ED: Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease. Blood 72:555, 1988.
34. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966.
35. Cox DR: Regression models and life tables. J R Stat Soc 34:187, 1972.
36. Schoenfeld DA: Sample size formula for the proportional hazards regression model. Biometrics 39:499, 1983.
37. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic marrow transplants. N Engl J Med 324:1005, 1991.
38. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, Buhles WC, DeArmond B, Meyers JD: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601, 1991.
39. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilber G, Buell D: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845, 1992.
40. Storb R, Deeg HJ, Pepe M, Appelbaum FR, Anasetti C, Beatty P, Bensinger W, Berenson R, Buckner CD, Clift R, Doney K, Longton G, Hansen J, Hill R, Loughran T Jr., Martin P, Singer J, Sanders J, Stewart P, Sullivan K, Witherspoon R, Thomas ED: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 73:1729, 1989.
41. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225, 1993.
42. Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM: Recovery after allogeneic marrow transplantation: Prospective study of predictors of long-term physical and psychosocial functioning. Bone Marrow Transplant 11:319, 1993.
43. Storek J, Ferrara S, Ku N, Giogri JV, Champlin RE, Saxon A: B cell reconstitution after human bone marrow transplantation: Recapitulation of ontogeny? Bone Marrow Transplant 12:387, 1993.
44. Cunningham-Rundles C, Siegal FP, Smithwick EM, Lion-Boulé A, Cunningham-Rundles S, O'Malley J, Barandun S, Good RA: Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 101:435, 1984.
45. Bunch C, for the Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia: Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. N Engl J Med 319:902, 1988.
46. Messori A, Rampazzo R, Scroccaro G, Martini N: Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation - A meta-analysis. Bone Marrow Transplant 13:163, 1994.
47. Winston DJ, Ho WG, Bartoni K, Champlin RE: Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 12:283, 1993.
48. Storb R, Pepe M, Anasetti C, Appelbaum FR, Beatty P, Doney K, Martin P, Stewart P, Sullivan KM, Witherspoon R, Bensinger W, Buckner CD, Clift R, Hansen J, Longton G, Loughran T, Petersen FB, Singer J, Sanders J, Thomas ED: What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? Blood 76:1037, 1990.
49. Ferrara JLM, Deeg HJ: Graft-versus-host disease. N Engl J Med 324:667, 1991.
50. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. Blood 80:2964, 1992.
51. Abe Y, Horiuchi A, Miyake M, Kimura S: Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139:5, 1994.
52. Aukrust P, Froland SS, Liabakk N-B, Müller F, Nordoy I, Hang C, Espevik T: Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84:2136, 1994.
53. Cottler-Fox M, Lynch M, Pickle LW, Cahill R, Spitzer TR, Deeg HJ: Some but not all benefits of intravenous immunoglobulin therapy after marrow transplantation appear to correlate with IgG trough levels. Bone Marrow Transplant 8:27, 1991.
54. Godeau B, Lesage S, Divine M, Wirquin V, Farcet JP, Bierling P: Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 82:1415, 1993.
55. Clark JG, Crawford SW, Madtes DK, Sullivan KM: Obstructive lung disease after allogeneic marrow transplantation. Ann Intern Med 111:368, 1989.
56. Schultz KR, Green GJ, Wensley D, Sargent MA, Magee JF, Spinelli JJ, Pritchard S, Davis JH, Rogers PCJ, Chan KW, Phillips GL: Obstructive lung disease in children after allogeneic bone marrow transplantation. Blood 84:3212, 1994.
57. Roifman CM, Levison H, Gelfand EW: High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1:1075, 1987.
58. Kimberley RP, Salmon JE, Bussel JB, Crow MK, Hilgartner MW: Modulation of mononuclear phagocyte function by intravenous gammaglobulin. J Immunol 132:745, 1984.
59. Stohl W: Cellular mechanisms in the in vitro inhibition of poke-weed mitogen-induced B cell differentiation by immunoglobulin for intravenous use. J Immunol 136:4407, 1986.